CN1411810A - Fatigue-resistant drug composition - Google Patents
Fatigue-resistant drug composition Download PDFInfo
- Publication number
- CN1411810A CN1411810A CN02143981A CN02143981A CN1411810A CN 1411810 A CN1411810 A CN 1411810A CN 02143981 A CN02143981 A CN 02143981A CN 02143981 A CN02143981 A CN 02143981A CN 1411810 A CN1411810 A CN 1411810A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- meglin
- agent
- thiamine
- fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a fatigue-relieving pharmaceutical composition having improved fatigue-relieving effect and high safety and takable over a long period. The fatigue-relieving pharmaceutical composition contains hepronicate and vitamin B compounds as active components.
Description
Technical field
The present invention relates to the antifatigue compositions.More particularly, relate to the antifatigue compositions that is used to improve and alleviate fatigue symptom.
Background technology
Past people has been developed various antifatigue compositions in order to improve and alleviate fatigue symptom.But these antifatigue compositions can not play the effect of fatigue alleviating fully, and have the safety issue when taking for a long time.
Summary of the invention
Therefore, the objective of the invention is, the antifatigue compositions that can play the effect of fatigue alleviating better, can take for a long time again is provided.
Present inventors are for addressing the above problem, furtherd investigate the ingredient of being prepared, found that, meglin and vitamin(e) B group material composition prepared, than independent use meglin of difference and vitamin(e) B group material, more can improve the effect of fatigue alleviating significantly, finish the present invention thus.
That is, the invention provides the antifatigue compositions, it is characterized in that containing meglin and vitamin(e) B group material as effective ingredient.
Description of drawings
Fig. 1 represents that the electricity irritation gastrocnemius is brought out the fatigue alleviating result of the test (gastrocnemius endurance ratio) of muscle fatigue in the test example 1.
The specific embodiment
The employed meglin of antifatigue compositions of the present invention (to call " pharmaceutical composition " in the following text) can be used as has the peripheral vasodilator that improves the blood flow effect, suppresses pharmacological effects such as platelet aggregation effect and dissolving cellulos effect.This chemical compound past is as slave's disease, too peripheral circulation disorderses, chilblain and the uses of cold injury medicaments such as cleaning (バ-ジ ャ-) disease, Arteriosclerosis obliterans.
In addition, the employed vitamin(e) B group material of pharmaceutical composition of the present invention can be enumerated vitamin B
1, B
2, B
5, B
6And B
12Deng, vitamin B preferably wherein
1And B
6Vitamin B
1Past is as general medicine, be used to alleviate neuralgia, lumbago, shoulder pain, senile shoulder various symptoms such as myalgia and arthralgia, numbness of hands and feet, constipation, eyestrain such as ache, and in beriberi, physical fatigue and gestation, age of sucking, disease take place, use during physically-draining after being ill.In addition, vitamin B
6Can be used for alleviating each symptom such as angular cheilitis, lip inflammation, stomatitis, glossitis, eczema, dermatitis, acne, and in gestation, age of sucking, disease, use during physically-draining after being ill.
The employed vitamin B of pharmaceutical composition of the present invention
1, that specifically can enumerate has the two thiamines of thiamine hydrochloride, thiamine nitrate, nitric acid, thiamine disulfide element, thiamine dotriacontyl sulfuric ester (チ ア ミ Application ジ セ チ Le sulphuric acid エ ス テ Le salt), hydrochloric acid dotriacontyl thiamine (hydrochloric acid ジ セ チ ア ミ Application), fursultiamine hydrochloride element, neuvitan, commetamin, two thiamine (PVC ス イ Block チ ア ミ Application), bisbentiamine, fursultiamine element, prosultiamine and a benfotiamine etc.They can be used alone or mixed use of two or more.
The employed vitamin B of pharmaceutical composition of the present invention
6, that specifically can enumerate has a hydrochloric acid vitamin B
6, the phosphoric acid vitamin B
6Aldehyde etc.They can be used alone or mixed use of two or more.
The mixed proportion of meglin and vitamin(e) B group material in the pharmaceutical composition of the present invention is decided according to used vitamin(e) B group material, and for example, the vitamin(e) B group material is a vitamin B
1The time, the meglin of common relative 1 part of weight, the vitamin B of use 0.003-10 part weight
1, more preferably use the vitamin B of 0.5-2 part weight
1In addition, the vitamin(e) B group material is a vitamin B
6The time, the meglin of common relative 1 part of weight, the vitamin B of use 0.017-10 part weight
6, more preferably use the vitamin B of 0.5-2 part weight
6
And pharmaceutical composition of the present invention can mix various ingredients as required.These ingredients can be enumerated vitamin substances beyond vitamin C and derivant, folic acid, vitamin D, K, H, A and rosin ester (レ チ ノ イ De) and these materials and the vitamin(e) B group material.The ingredient that also can enumerate is in addition, γ-Hi-Z, L-cysteine hydrochloride, L-cysteine, ursodesoxycholic acid, orotic acid, glucuronolactone, glucuronamide, colloid leucine sodium sulfate, processing Bulbus Allii, Radix Dauci Sativae, SEMEN COICIS etc., perhaps mineral such as calcium, ferrum, phosphorus, magnesium, potassium, copper, iodine, manganese, selenium, zinc, chromium, molybdenum.These ingredients can be used alone or mixed use of two or more in the scope that does not influence effect of the present invention.
Pharmaceutical composition of the present invention is that above-mentioned meglin, vitamin(e) B group material and required ingredient are mixed, and is formulated with the ordinary preparation method.
The preparation of described pharmaceutical composition can be used known formulation additives as required.These formulation additives can be enumerated stabilizing agent, surfactant, plasticizer, lubricant, smoothing preparation, solubilizing agent, Reducing agent, buffer agent, sweeting agent, host, adsorbent, flavoring agent, bonding agent, suspending agent, antioxidant, polishing material, coating agent, the agent shell, wetting agent, moistening regulator, filler, defoamer, freshener, coloring agent, fumet, spice, the sugar-coat agent, extender, softening agent, emulsifying agent, thickening agent, adhesion agent, foaming agent, the pH regulator agent, diluent and excipient, dispersant, disintegrating agent, the disintegrate adjuvant, disintegrate prolongs agent, aromatic, anti-blushing agent, antiseptic, preservative agent, lytic agent, the dissolving adjuvant, solvent, flowing agent, antistatic agent, extender, wetting agent and hygroscopic agent etc.
In addition, the dosage form of pharmaceutical composition of the present invention can be enumerated solid, semisolid and liquid preparation that oral forms such as tablet, granule, powder, capsule, soft capsule, pill, suspending agent, Emulsion, mixture for internal use, syrup, dry syrup are arranged.In addition, as required, also can form fine particles such as microcapsule, Nano capsule, microspheroidal and nanometer spherical after, make above-mentioned preparation.
Antifatigue compositions of the present invention owing to contain effective ingredient by meglin and vitamin(e) B group material mixed preparing, than independent use respectively they the time, the fatigue alleviating effect significantly improves.
Embodiment
Enumerate embodiment and test example detailed description the present invention below, but the present invention is not subjected to the qualification of these embodiment.
Embodiment 1
1g meglin, 1g bisbentiamine and 1g hydrochloric acid vitamin B
6Uniform mixing is made powder, obtains antifatigue compositions of the present invention.Comparative Examples 1
1g bisbentiamine and 1g hydrochloric acid vitamin B
6Uniform mixing is made the powder of Comparative Examples 1.
Embodiment 2
1g meglin, 1g fursultiamine hydrochloride element and 1g hydrochloric acid vitamin B
6Uniform mixing is made powder, obtains antifatigue compositions of the present invention.Comparative Examples 2
Plain and the 1g hydrochloric acid vitamin B the 1g fursultiamine hydrochloride
6Uniform mixing is made the powder of Comparative Examples 2.Test example 1
The electricity irritation gastrocnemius is brought out the fatigue alleviating test of muscle fatigue
(1) test method
Use the male wistar series rat (5 age in week) of going on a hunger strike in 18 hours in the fatigue alleviating test, 1 group 5 shared 25.Test medicine uses the embodiment of the invention 1 and 2, and the preparation that obtains in Comparative Examples 1 and 2.Each test medicine suspends with 0.5%CMC-Na (Carboxymethyl cellulose sodium), stimulate 15 minutes with 4Hz after, to intraduodenal administration.Dosage is 15mg/kg for embodiment 1 and 2 pharmaceutical composition, and Comparative Examples 1 and 2 pharmaceutical composition are 10mg/kg, the same 0.5%CMC-Na (5mL/kg) that uses during contrast.
In the test, with inserting injection needle in the animal duodenum of amido Ethyl formate anesthesia, be fixed on the abdomen position after, peel off the right hind gastrocnemius, use isometry pick off (オ リ エ Application テ ッ Network society system) record muscle contraction.
The fatigue alleviating test of gastrocnemius, following carrying out.That is, carry out electricity irritation (stimulation amplitude: 1.5msec, threshold voltage), after contraction is stable, stimulated 15 minutes, bring out muscle fatigue with 4Hz with 0.1Hz.After dropping into the appointment test medicine in each rat, stopped to stimulate 28 minutes, stimulated again 2 minutes with 4Hz then, stimulated equally in later per 30 minutes.Maximum shrinkage force when stimulating the maximum shrinkage force that obtains and bringing out muscle fatigue by 2 minutes is calculated rate of change by following formula, and this is gastrocnemius endurance ratio (%).
Give the gastrocnemius endurance ratio of test medicine after 90 minutes as shown in Figure 1.As illustrating among Fig. 1, comparing embodiment 1 and Comparative Examples 1, embodiment 2 and Comparative Examples 2, the administration group of antifatigue compositions of the present invention and Comparative Examples relatively, the gastrocnemius endurance ratio is little, obtains passing through vitamin B thus
1And vitamin B
6In mix meglin, can strengthen the result of fatigue alleviating effect.
Embodiment 3
100g meglin, 100g fursultiamine hydrochloride element and 100g hydrochloric acid vitamin B
6And behind the 100g corn starch uniform mixing, fill 200mg in each hard capsule, obtain the antifatigue compositions of the present invention of hard capsule.
Embodiment 4
500g meglin, 500g thiamine nitrate, 500g hydrochloric acid vitamin B
6, 740g lactose and 740g crystalline cellulose uniform mixing, cross No. 20 sieves after, remix 15g Talcum and 5g magnesium stearate obtain film-making agent powder.With the mortar of diameter 9.5mm, every 300mg film-making agent obtains the antifatigue compositions of the present invention of tablet.
Embodiment 5
200g meglin, 200g bisbentiamine, 200g hydrochloric acid vitamin B
6With the 1200g soybean oil, mix with commonsense method.The compositions that obtains is used soft capsule maker processing automatically continuously, obtains the antifatigue compositions of the present invention of the soft capsule of content 300g.
Claims (7)
1, antifatigue compositions is characterized in that containing meglin and vitamin(e) B group material as effective ingredient.
2, the described antifatigue compositions of claim 1, wherein the vitamin(e) B group material is a vitamin B
1Or vitamin B
6
3, the described antifatigue compositions of claim 2 is characterized in that vitamin B
1Be to be selected from the two thiamines of thiamine hydrochloride, thiamine nitrate, nitric acid, thiamine disulfide element, thiamine dotriacontyl sulfuric ester, hydrochloric acid dotriacontyl thiamine, fursultiamine hydrochloride element, neuvitan, commetamin, two thiamine, bisbentiamine, fursultiamine element, prosultiamine element and the benfotiamine one or more.
4, the described antifatigue compositions of claim 2 is characterized in that vitamin B
6Be to be selected from the hydrochloric acid vitamin B
6With the phosphoric acid vitamin B
6In the aldehyde etc. one or more.
5, each described antifatigue compositions in the claim 2 to 4 is characterized in that the meglin of relative 1 part of weight, uses the vitamin B of 0.003-10 part weight
1
6, each described antifatigue compositions in the claim 2 to 4 is characterized in that the meglin of relative 1 part of weight, uses the vitamin B of 0.017-10 part weight
6
7, each described antifatigue compositions in the claim 2 to 6 is characterized in that the meglin of relative 1 part of weight, uses the vitamin B of 0.003-10 part weight
1Vitamin B with 0.017-10 part weight
6
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001315820A JP2003119139A (en) | 2001-10-12 | 2001-10-12 | Fatigue relieving pharmaceutical composition |
| JP315820/2001 | 2001-10-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1411810A true CN1411810A (en) | 2003-04-23 |
| CN1244326C CN1244326C (en) | 2006-03-08 |
Family
ID=19133936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021439818A Expired - Fee Related CN1244326C (en) | 2001-10-12 | 2002-09-29 | Fatigue-resistant drug composition |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2003119139A (en) |
| KR (1) | KR20030030883A (en) |
| CN (1) | CN1244326C (en) |
| HK (1) | HK1054694A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5032310B2 (en) * | 2005-05-27 | 2012-09-26 | 興和株式会社 | Medicine for fatigue recovery |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01308232A (en) * | 1988-06-03 | 1989-12-12 | Takeda Chem Ind Ltd | Solid drug and production thereof |
| JP3942207B2 (en) * | 1995-02-17 | 2007-07-11 | 武田薬品工業株式会社 | Depressive symptom improving agent |
| JPH10287560A (en) * | 1997-04-11 | 1998-10-27 | Taisho Pharmaceut Co Ltd | Pharmaceutical composition |
| US6017946A (en) * | 1997-10-08 | 2000-01-25 | Posner; Robert | Serotonin containing formulation for oral administration and method of use |
| KR20010055274A (en) * | 1999-12-10 | 2001-07-04 | 김재수 | Health augmentation food for the anti fatigue |
-
2001
- 2001-10-12 JP JP2001315820A patent/JP2003119139A/en active Pending
-
2002
- 2002-09-29 CN CNB021439818A patent/CN1244326C/en not_active Expired - Fee Related
- 2002-10-07 KR KR1020020060905A patent/KR20030030883A/en not_active Application Discontinuation
-
2003
- 2003-09-30 HK HK03107056A patent/HK1054694A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244326C (en) | 2006-03-08 |
| KR20030030883A (en) | 2003-04-18 |
| HK1054694A1 (en) | 2003-12-12 |
| JP2003119139A (en) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1141095C (en) | Preparation containing combination of N-5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and N-(4 trifluoromethylphenyl)-2-cyano-3-hyroxycrotonic acid amide | |
| DE60019741T2 (en) | NANOPARTICLE COMPOSITIONS CONTAINING EPLERENONE | |
| PT90328B (en) | PROCESS OF PRODUCTION OF PROLONGED PREPARATIONS OF PROLONGED GASTRICALLY STAY | |
| EP0097523A2 (en) | Extended action controlled release compositions | |
| HUE031092T2 (en) | Controlled release preparations | |
| JPS584720A (en) | Analgesic medicinal composition | |
| EP0857064A1 (en) | Stabilised pharmaceutical preparations containing thyroid hormone | |
| CH647675A5 (en) | METHOD FOR PRODUCING MICROCAPSULES CONTAINING ACTIVE PHARMACEUTICAL COMPOUNDS. | |
| WO1999024023A2 (en) | FORMULATION OF A COMBINATION COMPRISED OF OPIOID AND α - ADRENERGIC AGONISTS AND THE APPLICATION THEREOF | |
| CN1244326C (en) | Fatigue-resistant drug composition | |
| DE10301105B4 (en) | Use of 2-amino-2H-quinazoline derivatives for the treatment of myeloproliferative disorders, hypertension and bronchodilation | |
| WO1998040085A1 (en) | Stable solid preparation containing vitamin d3 and tricalcium phosphate | |
| EP2161022B1 (en) | Production of phosphate connectors and phosphate connectors produced according to the method | |
| AU674934B2 (en) | Pharmaceutical compositions comprising paracetamol and L-cysteine or a precursor thereof | |
| EP0085544A1 (en) | The use of aralkanoic acids and esters for the treatment of myelogenous leukemia | |
| EP0099186A2 (en) | Pharmaceutical compositions | |
| CN1230172C (en) | Blood circulation improving agent | |
| HU221435B (en) | Pellet-based pharmaceutical composition of controlled release with high content of potassium-chloride, and process for it's production | |
| CA2090234C (en) | Method for providing improved analgesic effect | |
| CN1929830A (en) | Combination of an NMDA receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other CNA disorders, and method therefor | |
| DE2605243A1 (en) | Antirheumatic compsn. contg. pyrazole acetic acids - and dextropropoxyphen or tilidine as synergist to provide powerful, rapid and sustained analgesia | |
| JPS5849433A (en) | Production of microcapsule | |
| DE3340347A1 (en) | Use of flurbiprofen and ibuprofen | |
| JPH0569089B2 (en) | ||
| US3495005A (en) | Compositions and methods for suppressing appetite with combinations of amphetamine and thioridazine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060308 Termination date: 20100929 |